Sector News

House cleaning to re-Shape Alexion?

May 24, 2017
Life sciences

Alexion Pharmaceuticals Inc. continues to reshape its top-level management after the company was hit by an internal investigation into its sales practices.

Alexion will start a search for a new Chief Financial Officer after current CFO Dave Anderson announced he will resign at the end of August. Anderson had joined the company in December after more than a decade as CFO at Honeywell International Inc. He had replaced Vikas Sinha, who resigned last year along with CEO David Hallal during the sales practices investigation.

Ludwig Hantson was named named Alexion’s chief executive in March.

The company has appointed Brian Goff as Chief Commercial Officer, effective June 1. Goff is a veteran biopharmaceutical executive with more than 25 years of experience at companies including Neurovance, Inc., Baxalta, Inc., Baxter, Novartis and Johnson & Johnson.

Earlier this year, Alexion found that some of its senior management staff had pressured employees to get customers to order its flagship drug Soliris earlier than needed to meet financial targets

Source: RTT News

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach